Encouraging SRC Findings on Ph I/II Skin Cancer Trial

Encouraging SRC Findings on Ph I/II Skin Cancer Trial

Invion Limited (IVX:AU) has announced Encouraging SRC Findings on Ph I/II Skin Cancer Trial

Download the PDF here.

Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Invion Limited

Invion Limited

Revolutionizing Photodynamic Therapy (PDT) for cancer and infectious diseases Keep Reading...
Funded Collaboration Agreement with Protect Animal Health

Funded Collaboration Agreement with Protect Animal Health

Invion Limited (IVX:AU) has announced Funded Collaboration Agreement with Protect Animal HealthDownload the PDF here. Keep Reading...
Repayment of Lind Facility with Successful Capital Raise

Repayment of Lind Facility with Successful Capital Raise

Invion Limited (IVX:AU) has announced Repayment of Lind Facility with Successful Capital RaiseDownload the PDF here. Keep Reading...
Trading Halt

Trading Halt

Invion Limited (IVX:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
Appendix 4E and Annual Report

Appendix 4E and Annual Report

Invion Limited (IVX:AU) has announced Appendix 4E and Annual ReportDownload the PDF here. Keep Reading...
Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

Invion Limited (IVX:AU) has announced Orphan Drug Designation Granted by U.S. FDA For Anal CancerDownload the PDF here. Keep Reading...
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
Canadian Investment Regulatory Organization Trade Resumption - CRDL

Canadian Investment Regulatory Organization Trade Resumption - CRDL

Trading resumes in: Company: Cardiol Therapeutics Inc. TSX Symbol: CRDL All Issues: Yes Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly... Keep Reading...
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch in 2025

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
FY25 Preliminary Results Summary and Company Update

FY25 Preliminary Results Summary and Company Update

Cardiex Limited (CDX:AU) has announced FY25 Preliminary Results Summary and Company UpdateDownload the PDF here. Keep Reading...
Appendix 4E

Appendix 4E

Cardiex Limited (CDX:AU) has announced Appendix 4EDownload the PDF here. Keep Reading...
Invion Limited

Invion Limited Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News